DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus® DehydraTECH-semaglutide reduces gastrointestinal side effects by 43.5% as compared to Rybelsus® DehydraTECH-GLP-1 study arms evidencing patient safety and tolerability… Read More
Long-term INM-901 treatment in preclinical studies in advanced disease continues to show multi-modal activity VANCOUVER, BC – InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused… Read More
LONDON, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, provides the following update from its wholly owned subsidiary Inaphaea BioLabs… Read More
UBC Faculty of Medicine professor Dr. Paul Anthony Keown has been awarded the Clinical Trials BC Leadership & Advocacy Award for his outstanding contributions to organ transplant research, clinical trials… Read More
Bausch Health Announces the Appointment of Two New Members to Its Board of Directors LAVAL, QC – Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, announced the appointment… Read More
